Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02643550 |
Recruitment Status :
Active, not recruiting
First Posted : December 31, 2015
Last Update Posted : February 9, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The objective of this study is to evaluate in a 3 +3 design, the safety of escalating doses of Monalizumab given IV in combination with cetuximab in patients who have received prior systemic regimen(s) for recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).
Cohorts expansion will evaluate antitumor activity of monalizumab and cetuximab with or without anti-PD(L)1
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Head and Neck Neoplasms | Biological: Monalizumab Biological: Cetuximab Biological: Anti-PD(L)1 | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 143 participants |
Allocation: | Non-Randomized |
Intervention Model: | Sequential Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase 1b/2 Trial of IPH2201 And Cetuximab in Patients With Human Papillomavirus (HPV) (+) and HPV (-) Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
Study Start Date : | December 2015 |
Estimated Primary Completion Date : | September 2022 |
Estimated Study Completion Date : | September 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: Dose escalation
Dose escalation of monalizumab in combination with cetuximab
|
Biological: Monalizumab
Other Name: IPH2201 Biological: Cetuximab |
Experimental: Expansion cohort 1
monalizumab + cetuximab expansion cohort
|
Biological: Monalizumab
Other Name: IPH2201 Biological: Cetuximab |
Experimental: Expansion cohort 2
monalizumab + cetuximab expansion cohort in patients with prior exposure to PD-(L)1 blockers
|
Biological: Monalizumab
Other Name: IPH2201 Biological: Cetuximab |
Experimental: Expansion cohort 3
monalizumab + cetuximab + anti-PD(L)1
|
Biological: Monalizumab
Other Name: IPH2201 Biological: Cetuximab Biological: Anti-PD(L)1 |
- Occurrence of Dose Limiting Toxicities (DLT) in the dose escalation part of the study [ Time Frame: within 4 weeks after first administration ]To assess the occurrence of Drug Limited Toxicities (DLTs)
- Objective Response Rate for expansion cohorts [ Time Frame: up to 12 months ]rate of patients in complete or partial response according to RECIST 1.1.
- Objective Response Rate for dose escalation part of the study [ Time Frame: up to 12 months ]rate of patients in complete or partial response according to RECIST 1.1
- Duration of Response for expansion cohorts [ Time Frame: From confirmed response until disease progression, up to 12 months ]Duration of complete and partial response
- Progression Free Survival for expansion cohorts [ Time Frame: Until disease progression or death, up to 2 years ]time between the start of treatment and the first documented progression or death
- Overall Survival for expansion cohorts [ Time Frame: Until death, up to 2 years ]time between the start of treatment and death

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Main Inclusion Criteria:
- Age ≥ 18 years
- Histologically or cytologically-confirmed, HPV (+) or HPV (-) squamous cell carcinoma of the nasopharynx (WHO Type 1), oropharynx, hypopharynx, larynx (supraglottis, glottis, subglottis) or oral cavity.
- Recurrent or metastatic disease, documented by imaging (CT scan, MRI, X-ray) and/or physical examination with measurable disease as per Response Evaluation Criteria in Solid Tumors [RECIST] 1.1
For phase II cohorts:
- Cohort #1: Patients who received a maximum of two prior systemic regimens for recurrent and/or metastatic disease and not amenable to further therapy with curative intent
- Cohort #2: Patients with R/M SCCHN not amenable to therapy of curative intent, who have received a maximum of two prior systemic regimens in the R/M setting and who have received prior PD-(L)1 blockers
- Cohort #3: Patients with R/M SCCHN who have not received prior systemic regimens in the R/M setting and who have not received prior PD-(L)1 inhibitors
Main Exclusion Criteria:
- For phase II cohort #1 and cohort #2: Patients who received more than 2 prior systemic regimens for recurrent and/or metastatic disease (no restriction in the phase Ib part of the trial).
- For phase II cohort #1 and cohort #2: Patients who received cetuximab or another inhibitor of epidermal growth factor receptor are excluded from the phase II of the trial, except if cetuximab was given as part of a primary treatment approach, with no progressive disease for at least 4 months following the end of prior cetuximab treatment.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02643550

Responsible Party: | Innate Pharma |
ClinicalTrials.gov Identifier: | NCT02643550 |
Other Study ID Numbers: |
IPH2201-203 |
First Posted: | December 31, 2015 Key Record Dates |
Last Update Posted: | February 9, 2021 |
Last Verified: | February 2021 |
Carcinoma, Squamous Cell Squamous Cell Carcinoma of Head and Neck Head and Neck Neoplasms Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type |
Neoplasms Neoplasms, Squamous Cell Neoplasms by Site Cetuximab Antineoplastic Agents, Immunological Antineoplastic Agents |